TY - JOUR
T1 - Baclofen and gastroesophageal reflux disease
T2 - Seeing the forest through the trees editorial
AU - Clarke, John O.
AU - Fernandez-Becker, Nielsen Q.
AU - Regalia, Kirsten A.
AU - Triadafilopoulos, George
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Baclofen has been shown to decrease reflux events and increase lower esophageal sphincter pressure, yet has never established a clear role in the treatment of gastroesophageal reflux disease (GERD). Lei and colleagues have shown in a recent elegant study that baclofen reduces the frequency and initiation of secondary peristalsis and heightens esophageal sensitivity to capsaicin-mediated stimulation. These findings may help explain both the benefit of baclofen in conditions such as rumination and supragastric belching, as well as the apparent lack of benefit of baclofen and other GABAB agonists in long-term treatment of GERD.
AB - Baclofen has been shown to decrease reflux events and increase lower esophageal sphincter pressure, yet has never established a clear role in the treatment of gastroesophageal reflux disease (GERD). Lei and colleagues have shown in a recent elegant study that baclofen reduces the frequency and initiation of secondary peristalsis and heightens esophageal sensitivity to capsaicin-mediated stimulation. These findings may help explain both the benefit of baclofen in conditions such as rumination and supragastric belching, as well as the apparent lack of benefit of baclofen and other GABAB agonists in long-term treatment of GERD.
UR - http://www.scopus.com/inward/record.url?scp=85044642974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044642974&partnerID=8YFLogxK
U2 - 10.1038/s41424-018-0010-y
DO - 10.1038/s41424-018-0010-y
M3 - Review article
C2 - 29599487
AN - SCOPUS:85044642974
SN - 2155-384X
VL - 9
JO - Clinical and translational gastroenterology
JF - Clinical and translational gastroenterology
IS - 3
M1 - 0010
ER -